BioScrip third quarter income increases 2.

The Pharmacy Solutions segment produced $15.4 million of segment Adjusted EBITDA, or 4.5 percent of segment revenue. This comes even close to $10.7 million, or 3.3 percent of segment revenue in the last year. Pharmacy Solutions segment Adjusted EBITDA elevated because of growth in discount money card program volumes, fresh managed care contracts, development in oncology, arthritis and multiple sclerosis therapies, and industry-wide drug inflation. Furthermore, a decrease was experienced by the Pharmacy Solutions segment in bad personal debt expense. Altogether, consolidated bad debt expenditure reduced from $5.3 million this year 2010 to $3.7 million in 2011. On a consolidated basis, BioScrip reported $19.0 million of Altered EBITDA through the third quarter of 2011, or 4.2 percent of total revenue, in comparison to $18.1 million, or 4.1 percent of total revenue in the last year. Continue reading

Safety and immune response of AGS-003 treatment.

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO Argos Therapeutics today announced the display of positive interim data from a Stage 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in conjunction with sunitinib, in patients with diagnosed advanced renal cell carcinoma recently ?boldenone undecylenate side effects . The info were discussed June 7 in a poster program at the 46th Annual Getting together with of the American Culture of Clinical Oncology , kept in Chicago, IL.D., Ph.D., Co-Director, Immunotherapy Program for the Blumenthal Cancers Center in Charlotte, NEW YORK and lead writer on the poster. Continue reading

SUNY Upstate Medical University partner in comparative study of biomaterials Amedica Corporation.

With this state-of-the-art RSA technology features, the University is qualified to execute this advanced materials study uniquely, said Mike H. Sunlight, M.D., orthopaedic cosmetic surgeon and business lead investigator in the analysis at SUNY Upstate Medical University. Shappley says he believes the analysis will make a difference to surgeons as they continue steadily to strive for new technology that improve patient treatment.. Amedica, SUNY Upstate Medical University partner in comparative study of biomaterials Amedica Corporation, a spinal and orthopaedic implant and instrument manufacturer focused on unique silicon nitride ceramic technology, announced that it has entered into an contract with SUNY Upstate Medical University to conduct an additional research study that evaluates the company’s SiN ceramic technology in comparison to PEEK interbody fusion gadgets. Continue reading

Page 4 of 41234